Journal of Infectious Diseases & Therapy
Open Access

In patients infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), disorders that have developed within three months of the onset of coronavirus disease 2019 (COVID-19) and persisted for at least two months as those that cannot be explained by other diseases are defined as post COVID-19 conditions (long COVID) by the World Health Organization (WHO) [1]. As of January 2023 in the Unites States, the ratio of patients who have suffered from symptoms of long COVID at least once is 15% of the overall adult population, and the symptoms have still persisted in 6% of those patients [2].

In long COVID, there are at least 200 different symptoms including headache, fatigue, and taste and smell disorders, in addition to general symptoms such as fatigue, shortness of breath, and cognitive impairment [3,4], which have been reported to persist even one year or longer after onset in some patients [5]. However, the causes of persistence of those individual symptoms are unknown in general, and most guidelines for management of long COVID just recommend conducting adjunctive therapy and rehabilitation depending on the patient’s symptoms [6-8]; the treatment methods are still being developed.

Zinc is one of the essential trace elements for survival of organisms, which has been shown to play a role in the functions of more than 300 different types of enzymes and at least 1,000 transcription factors [9], and in memory and recognition while existing at a higher concentration in brain cells [10]. Moreover, zinc deficiency may cause delayed wound healing, reproductive dysfunction, taste disorder, and compromised condition [11-13].

As for the relationship between COVID-19 and zinc, lower serum zinc concentration in COVID-19 patients compared to unaffected individuals, potential increase in SARS-CoV-2 infection with zinc deficiency, and zinc deficiency as a risk factor for death and severe conditions due to COVID-19 have been reported [14-21]. Therefore, the benefits of zinc supplementation are expected in COVID-19 patients with hypozincemia.

Abdallah, et al., reported that oral zinc administration decreased 30- day mortality, ICU admission rate, symptom duration, and length of hospital stay as compared to placebo in COVID-19 patients [22]. Gordon, et al., reported that zinc supplementation was effective for prevention of and decrease in COVID-19 in a case-control study [23]. On the other hand, a randomized controlled trial by Thomas, et al., was terminated early after zinc was considered not beneficial, showing no significant reduction in symptom duration [24]. Thus, no consistent opinions have been obtained by clinical assessments of zinc supplementation for COVID-19. In this review, we discuss the potential effects of zinc supplementation on long COVID.

Literature Review

Actual zinc intake and diagnostic criteria, treatment guide, and factors of zinc deficiency in Japanese population. Recommended amounts of zinc intake in Japanese population are 11 mg/day in adult men (10 mg/day in men aged 75 years or older) and 8 mg/day in adult women (the amounts to be added for pregnant and lactating women are 2 mg/day and 3 mg/day, respectively) [25], while the actual amounts taken were lower than the recommended amounts in individuals other than women aged 60 to 79 years based on the National Health and Nutrition Examination Survey in 2019 [26]. In Japan, a condition with serum zinc concentration at less than 60 μg/dL is defined as zinc deficiency, and intake of zinc at 50 to 100 mg/day is recommended in patients with zinc deficiency [27].

Primary factors of zinc deficiency are inadequate intake, absorption defect, increased requirement, and enhanced excretion of zinc [27,28]. Additionally, patients with liver disease, diabetes mellitus, and kidney disease, as well as those on dialysis are more likely to develop zinc deficiency [27,29]. Elderly people tend to develop a chronic disease with higher long-term administration rate of an oral chelating drug. Pregnant women and low birth weight infants who require a higher amount of zinc are also at risk for zinc deficiency [27].

Major symptoms of hypozincemia

There are various symptoms of zinc deficiency. Zinc is associated with protein synthesis in the epidermis, and zinc deficiency may cause dermatitis due to decreased epidermal Langerhans’ cells, and conditions such as hair loss related to skin disorders around the hair follicles [30]. Lower serum zinc concentration has also been reported in patients with hair loss as compared to healthy individuals. Kil, et al., reported that in patients with hair loss, mean serum zinc was 84.33± 22.88, significantly lower than the control group (97.94 ± 21.05 μg/dL) [31]. Furthermore, hypozincemia may induce taste disorder [13,32,33]. Since zinc is distributed in the epithelial cells of the tongue, and the taste buds and regions around the gustatory pores contain zincdependent enzymes such as alkaline phosphatase, zinc deficiency has been considered to cause taste disorder by a decrease in the number and size of the taste buds and its morphologic changes [34].

Meta-analyses by Swardfager, et al., showed lower serum zinc concentration in patients with depression, onset of depressive symptoms with serum zinc concentration at 1.8 M or lower [35], and various neurologic symptoms that may be caused by zinc deficiency [36,37]. Some reports showed that patients with refractory depression started to feel better after zinc supplementation [38,39].

Zinc deficiency may also cause imbalance between functions of the T helper 1 and 2 cells, leading to a decrease in the production of immune interferon-gamma and interleukin-2, and may increase inflammatory cytokine production and reduction in chemotaxis and phagocytosis of polymorphonuclear cells, resulting in compromised conditions by various routes [40-42]. Additionally, zinc deficiency is known to cause anemia, developmental disorders, gonadal failure, and gastrointestinal dysfunction with symptoms such as diarrhoea [27,43].

Similar and overlapped points of symptoms in long COVID and hypozincemia

Symptoms related to long COVID include fatigue, shortness of breath, cognitive impairment, and others that may affect daily living including headache, fatigue, and taste and smell disorders. Taste and smell disorders and hair loss that are observed by hypozincemia have also been reported in long COVID [44-46]. Although the pathogenesis of each symptom is unknown in COVID-19, a significantly lower serum zinc concentration has been reported in COVID-19 patients as compared to healthy individuals [16,47-50]. For example, Jothimani, et al., found a median serum zinc level of 74.5 (interquartile range 53.4-94.6) μg/dL in COVID-19 patients, which was significantly lower than the median level of 105.8 (interquartile range 95.65-120.90) μg/ dL in healthy controls (p<0.001)[16]. Keleş, et al., also reported significantly lower median serum zinc levels in COVID-19 patients (88.5 μg/dL, IQR 77.2-100) compared to the control group (98 μg/dL, IQR 84-111) (p=0.001) [48]. Pvsn, et al., reported that serum zinc levels in COVID-19 patients were 8% lower than in the control group [50]. Overall, there is roughly an 8-31 μg/dL difference in zinc levels between healthy individuals and COVID-19 patients, although results varied depending on the study. In the meantime, the relationship between zinc and taste disorder has not yet been shown in COVID-19 patients

Moreover, the most common symptom of long COVID accompanied by hypozincemia was reportedly general fatigue [51,52]. Al-Hakeim, et al., concluded that chronic fatigue was relate to inflammation and neuro-oxidative toxicity [51].

Role of zinc for symptoms related to long COVID

Zinc supplementation is known to show efficacy for common sleep disorders [53,54]. Based on a narrative review by Pak, et al., zinc may be one of the essential trace elements to alleviate symptoms related to long COVID and improve inflammation and the quality of patient’s sleep [55]. Moreover, zinc may be a trace element that strongly enhances hair follicle regeneration [56]. Hair loss related to COVID-19 is considered as Telogen Effluvium (TE) that may be associated with dysregulation of the hair growth cycle, being one of the causes of diffuse hair loss [57]. It is reported that serum zinc concentrations in patients with common TE were significantly lower than the values in non-TE patients [31], and zinc supplementation was effective for TE [58]. In addition, zinc supplementation is recommended in patients who developed hair loss after the onset of COVID-19 with a lower baseline serum zinc concentration [59]. A report showed that hair loss related to COVID was improved sooner in patients who received zinc supplementation as compared to those without a prescription of zinc [60]. The improvement rate of the group treated with zinc acetate hydrate was 73.3% after 4 weeks, 86.7% after 8 weeks, and 93.3% after 12 weeks, showing a significant difference from the nonadministration group from an early stage. It was supporting the benefit of zinc supplementation for COVID-19.

Zinc supplementation was effective for taste disorder accompanied by hypozincemia in some reports [61-64], and others recommended zinc supplementation for taste disorder related to COVID-19 [8,65]. However, taste disorder was not improved in a study which examined the effects of zinc preparation administration on the improvement of individual symptoms in patients with long COVID [60]. Some studies suggested possibilities that the binding capacity of SARS-CoV-2 to Angiotensin Converting Enzyme-2 (ACE-2) receptors which are highly expressed on the surfaces of the tongue and the oral mucosa, may be associated with the pathogenesis of taste disorder related to COVID-19 and that the SARS-CoV-2 invading via the sialic acid receptors may inhibit the transport of taste substances via glycoproteins, leading to loss of taste [66-68]. It is also shown that infection and replication of the SARS-CoV-2 may occur in the taste cells [69], and that inflamed taste buds may be associated with taste disorder [70]. Taste disorder may reportedly be correlated with Interleukin-6 (IL-6), an inflammatory cytokine [71], which may be indirectly responsible for damage to the gustatory receptors due to SARS-CoV-2 infection in the epithelial cells and subsequent local inflammation [72-74]. No definitive treatment method for taste disorder related to COVID-19 has been established. However, a rehabilitation method has been developed, and the efficacy of corticosteroid pastes has been reported [75,76].

Zinc supplementation has shown to decrease neuro-oxidative toxicity [77]. COVID-19 may affect the Central Nervous System (CNS) [78,79], and frequently cause neuropsychiatric symptoms such as depression [80]. It is said that the onset of depression related to COVID-19 may be associated with social factors including stress and financial problems, and pathological factors such as inflammation due to invasion of pro-inflammatory cytokines into the CNS [81], while zinc supplementation has been shown to be effective as an approach in the pathological aspect of neuropsychiatric manifestations related to COVID-19 [82].

Based on the above reports, zinc supplementation may be effective for sleep disorder, hair loss, neuropsychiatric symptoms, and taste disorder related to long COVID accompanied by hypozincemia. However, since the pathogenesis of long COVID is still unknown, we are not uncertain whether or not zinc supplementation can lead to a comprehensive solution, and may become just an adjunctive therapy eventually. A multidirectional approach is required for hypozincemia which symptoms were not improved even by zinc supplementation.

1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, et al. (2022) A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22: e102-e107.

   [Crossref] [Google Scholar] [PubMed]

2. Long COVID: What Do the Latest Data Show? (2023) Kaiser Family Foundation.
3. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, et al. (2021) Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38: 101019.

   [Crossref] [Google Scholar] [PubMed]

4. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, et al. (2021) Characterising long COVID: A living systematic review. BMJ Glob Health 6: e005427.

   [Crossref] [Google Scholar] [PubMed]

5. Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, et al. (2022) Persistent symptoms in adult patients 1 year after Coronavirus Disease 2019 (COVID-19): A prospective cohort study. Clin Infect Dis 74: 1191-1198.

   [Crossref] [Google Scholar] [PubMed]

6. NICE guideline (2022) COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and Royal College of General Practitioners (RCGP).

   [PubMed]

7. (2023) Clinical management of COVID-19: Living guideline, World Health Organization.
8. COVID-19 Medical Care Guide (Separate Volume) (2022) Management of post-infected symptoms version 2.0: management of post-infected symptoms editorial committee.
9. Prasad AS (2013) Discovery of human zinc deficiency: Its impact on human health and disease. Adv Nutr 4: 176-190.

   [Crossref] [Google Scholar] [PubMed]

10. Sensi SL, Paoletti P, Bush AI, Sekler I (2009) Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 10: 780-791.

    [Crossref] [Google Scholar] [PubMed]

11. Heyneman CA (1996) Zinc deficiency and taste disorders. Ann Pharmacother 30: 186-187.

    [Crossref] [Google Scholar] [PubMed]

12. Roohani N, Hurrell R, Kelishadi R, Schulin R (2013) Zinc and its importance for human health: An integrative review. J Res Med Sci 18: 144-157.

    [Google Scholar] [PubMed]

13. Kogan S, Sood A, Garnick MS (2017) Zinc and wound healing: A review of zinc physiology and clinical applications. Wounds 29: 102-106. [Crossref]

    [Google Scholar] [PubMed]

14. Elham AS, Azam K, Azam J, Mostafa L, Nasrin B, et al. (2021) Serum vitamin D, calcium, and zinc levels in patients with COVID-19. Clin Nutr ESPEN 43: 276-282

    [Crossref] [Google Scholar] [PubMed]

15. Ghanei E, Baghani M, Moravvej H, Talebi A, Bahmanjahromi A, et al. (2022) Low serum levels of zinc and 25-hydroxyvitmain D as potential risk factors for COVID-19 susceptibility: A pilot case-control study. Eur J Clin Nutr 76: 1297-1302.

    [Crossref] [Google Scholar] [PubMed]

16. Jothimani D, Kailasam E, Danielraj S, Nallathambi B, Ramachandran H, et al. (2020) COVID-19: Poor outcomes in patients with zinc deficiency. Int J Infect Dis 100: 343-349.

    [Crossref] [Google Scholar] [PubMed]

17. Jahromi SR, Tabriz HM, Togha M, Ariyanfar S, Ghorbani Z, et al. (2021) The correlation between serum selenium, zinc, and COVID-19 severity: An observational study. BMC Infect Dis 21: 899.

    [Crossref] [Google Scholar] [PubMed]

18. Vogel-González M, Talló-Parra M, Herrera-Fernándezet V, Pérez-Vilaró G, Chillón M, et al. (2021) Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. Nutrients 13: 562.

    [Crossref] [Google Scholar] [PubMed]

19. Maares M, Hackler J, Haupt A, Heller RA, Bachmann M, et al. (2022) Free Zinc as a predictive marker for COVID-19 mortality risk. Nutrients 14: 1407.

    [Crossref] [Google Scholar] [PubMed]

20. Wessels I, Rolles B, Slusarenko AJ, Rink L (2022) Zinc deficiency as a possible risk factor for increased susceptibility and severe progression of Corona Virus Disease 19. Br J Nutr 127: 214-232.

    [Crossref] [Google Scholar] [PubMed]

21. Matsuoka N, Mizutani T, Kawakami K (2022) Biomarkers related to the prognosis of hospitalized COVID-19 patients Japanese J Hospital General Med 18: 349-357.
22. Abdallah SB, Mhalla Y, Trabelsi I, Sekma A, Youssef R, et al. (2023) Twice-daily oral zinc in the treatment of patients with coronavirus disease 2019: A randomized double-blind controlled trial. Clin Infect Dis 76: 185-191.

    [Crossref] [Google Scholar] [PubMed]

23. Gordon AM, Hardigan PC (2021) A case-control study for the effectiveness of oral zinc in the prevention and mitigation of COVID-19. Front Med (Lausanne) 8: 756707.

    [Crossref] [Google Scholar] [PubMed]

24. Thomas S, Patel D, Bittel B, Wolski K, Wang Q, et al. (2021) Effect of high-dose zinc and ascorbic acid supplementation vs. usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: The COVID A to Z randomized clinical trial. JAMA Netw Open 4: e210369

    [Crossref] [Google Scholar] [PubMed]

25. A clinical case definition of post-COVID-19 condition by a Delphi consensus
26. Crossref
27. Kodama H, Itakura H, Ohmori H, Sasaki M, Sando K, et al. (2018) Practice guideline for zinc deficiency. J Jpn Soc Clin Nutr 40: 120-167.
28. King JC, Cousins RJ, Tucker KL, Ziegler TR (2014) Zinc. In: Modern Nutrition in Health and Disease. (11th ed), Wolters Kluwer Health Adis (ESP) Baltimore, MD, USA, P:1616.
29. Yanagisawa H (2004) Zinc deficiency and clinical practice. JMAJ 47: 359-364.

    [Google Scholar]

30. Kawamura T, Ogawa Y, Nakamura Y, Nakamizo S, Ohta Y, et al. (2012) Severe dermatitis with loss of epidermal Langerhans cells in human and mouse zinc deficiency. J Clin Invest 122: 722-732.

    [Crossref] [Google Scholar] [PubMed]

31. Kil MS, Kim CW, Kim SS (2013) Analysis of serum zinc and copper concentrations in hair loss. Ann Dermatol 25: 405-409.

    [Crossref] [Google Scholar] [PubMed]

32. Ikeda M, Hirai R, Shuntaro S, Ikui A (2008) Taste disorders and zinc deficiency. Int J Oral-Med Sci 6: 105-111.

    [Crossref] [Google Scholar]

33. Yagi T, Asakawa A, Ueda H, Ikeda S, Miyawaki S, et al. (2013) The role of zinc in the treatment of taste disorders. Recent Pat Food Nutr Agric 5: 44-51.

    [Crossref] [Google Scholar] [PubMed]

34. Ikeda M (2004) Sensory dysfunctions due to trace element deficiencies and the clinical aspects taste and olfactory disorders. JMAJ 47(8): 387-390.

    [Google Scholar]

35. Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, et al. (2013) Zinc in depression: A meta-analysis. Biol Psychiatry 74: 872-878.

    [Crossref] [Google Scholar] [PubMed]

36. Szewczyk B (2013) Zinc homeostasis and neurodegenerative disorders. Front Aging Neurosci 5: 33.

    [Crossref] [Google Scholar] [PubMed]

37. Petrilli MA, Kranz TM, Kleinhaus K, Joe P, Getz M, et al. (2017) The emerging role for zinc in depression and psychosis. Front Pharmacol 8: 414.

    [Crossref] [Google Scholar] [PubMed]

38. Nowak G, Siwek M, Dudek D, Zieba A, Pilc A (2003) Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol 55: 1143-1147.

    [Google Scholar] [PubMed]

39. Siwek M, Dudek D, Paul IA, Sowa-Kućma M, Zieba A, et al. (2009) Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study. J Affect Disord 118: 187-195.

    [Crossref] [Google Scholar] [PubMed]

40. Prasad AS (2000) Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J Infect Dis 182: S62-S68.

    [Crossref] [Google Scholar] [PubMed]

41. Foster M, Samman S (2012) Zinc and regulation of inflammatory cytokines: Implications for cardiometabolic disease. Nutrients 4: 676-694.

    [Crossref] [Google Scholar] [PubMed]

42. Gammoh NZ, Rink L (2017) Zinc in infection and inflammation. Nutrients 9: 624.

    [Crossref] [Google Scholar] [PubMed]

43. Black MM (1998) Zinc deficiency and child development. Am J Clin Nutr 68: 464S-469S.

    [Crossref] [Google Scholar] [PubMed]

44. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R, et al. (2020) Smell and taste dysfunction in patients with COVID-19: A systematic review and meta-analysis. Mayo Clin Proc 95: 1621-1631.

    [Crossref] [Google Scholar] [PubMed]

45. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T (2020) The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: A systematic review and meta-analysis. Otolaryngol Head Neck Surg 163: 3-11.

    [Crossref] [Google Scholar] [PubMed]

46. Nguyen B, Tosti A (2022) Alopecia in patients with COVID-19: A systematic review and meta-analysis. JAAD Int 7: 67-77.

    [Crossref] [Google Scholar] [PubMed]

47. Yasui Y, Yasui H, Suzuki K, Saitou T, Yamamoto Y, et al. (2020) Analysis of the predictive factors for a critical illness of COVID-19 during treatment relationship between serum zinc level and critical illness of COVID-19. Int J Infect Dis 100: 230-236.

    [Crossref] [Google Scholar] [PubMed]

48. Keleş YE, Çiftdoğan DY, Çolak A, Aksay AK, Üstündag G, et al. (2022) Serum zinc levels in pediatric patients with COVID-19. Eur J Pediatr 181: 1575-1584.

    [Crossref] [Google Scholar] [PubMed]

49. Almasaud AS, Chalabi J, Arfaj AA, Qarni AA, Alkroud A, et al. (2023) Association of serum zinc and inflammatory markers with the Severity of COVID-19 infection in adult patients. Nutrients 15: 340.

    [Crossref] [Google Scholar] [PubMed]

50. Pvsn KK, Tomo S, Purohit P, Sankanagoudar S, Charan J, et al. (2023) Comparative analysis of serum zinc, copper and magnesium level and their relations in association with severity and mortality in SARS-CoV-2 patients. Biol Trace Elem Res 201: 23-30.

    [Crossref] [Google Scholar]

51. Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M (2023) Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry 28: 564-578.

    [Crossref] [Google Scholar] [PubMed]

52. Matsuda Y, Tokumasu K, Otsuka Y, Sunada N, Honda H, et al. (2023) Symptomatic characteristics of hypozincemia detected in long COVID patients. J Clin Med 12: 2062.

    [Crossref] [Google Scholar] [PubMed]

53. Ji X, Grandner AM, Liu J (2017) The relationship between micronutrient status and sleep patterns: A systematic review. Public Health Nutr 20: 687-701.

    [Crossref] [Google Scholar] [PubMed]

54. Baradari AG, Alipour A, Mahdavi A, Sharifi H, Nouraei SM, et al. (2018) The effect of zinc supplementation on sleep quality of ICU nurses: A double blinded randomized controlled trial. Workplace Health Saf 66: 191-200.

    [Crossref] [Google Scholar] [PubMed]

55. Pak VM, Lee J (2022) Examining the role of micronutrients on improving long COVID sleep-related symptoms. J Clin Nurs.

    [Crossref] [Google Scholar] [PubMed]

56. Plonka PM, Handjiski B, Popik M, Michalczyk D, Paus R (2005) Zinc as an ambivalent but potent modulator of murine hair growth in vivo- preliminary observations. Exp Dermatol 14: 844-853.

    [Crossref] [Google Scholar] [PubMed]

57. Olds H, Liu J, Luk K, Lim HW, Ozog D, et al. (2021) Telogen effluvium associated with COVID-19 infection. Dermatol Ther 34: e14761.

    [Crossref] [Google Scholar] [PubMed]

58. Karashima T, Tsuruta D, Hamada T, Ono F, Ishii N, et al. (2012) Oral zinc therapy for zinc deficiency-related telogen effluvium. Dermatol Ther 25: 210-213.

    [Crossref] [Google Scholar] [PubMed]

59. Popescu MN, Berteanu M, Beiu C, Popa LG, Mihai MM, et al. (2022) Complementary strategies to promote hair regrowth in post-COVID-19 telogen effluvium. Clin Cosmet Investig Dermatol 15:735-743.

    [Crossref] [Google Scholar] [PubMed]

60. Matsuoka N, Mizutani T, Kawakami K (2023) Symptom profile of patients with post-COVID-19 conditions and influencing factors for recovery. J Clin Med Res 15: 116-126.

    [Crossref] [Google Scholar] [PubMed]

61. Yoshida S, Endo S, Tomita H (1991) A double-blind study of the therapeutic efficacy of zinc gluconate on taste disorder. Auris Nasus Larynx 18: 153-161.

    [Crossref] [Google Scholar] [PubMed]

62. Sakai F, Yoshida S, Endo S Tomita H (2002) Double-blind, placebo-controlled trial of zinc picolinate for taste disorders. Acta Otolaryngol Suppl 546:129-133.

    [Crossref] [Google Scholar] [PubMed]

63. Tanaka M, Oki Y, Katano H, Syoda Y, Oshima T (2020) The study of administration of zinc acetate hydrate for taste disorder with hypozincemia. J Zinc Nutritional Ther 10: 82-87.
64. Mozaffar B, Ardavani A, Muzafar H, Idris I (2023) The effectiveness of zinc supplementation in taste disorder treatment: A systematic review and meta-analysis of randomized controlled trials. J Nutr Metab 2023: 6711071.

    [Crossref] [Google Scholar] [PubMed]

65. Santos HO (2022) Therapeutic supplementation with zinc in the management of COVID-19–related diarrhea and ageusia/dysgeusia: mechanisms and clues for a personalized dosage regimen. Nutr Rev 80:1086-1093.

    [Crossref] [Google Scholar] [PubMed]

66. Aziz M, Perisetti A, Lee-Smith WM, Gajendran M, Bansal P, et al. (2020) Taste changes (dysgeusia) in COVID-19: A systematic review and meta-analysis. Gastroenterology 159: 1132-1133.

    [Crossref] [Google Scholar] [PubMed]

67. Eshraghi AA, Mirsaeidi M, Davies C, Telischi FF, Chaudhari N, et al. (2020) Potential mechanisms for COVID-19 induced anosmia and dysgeusia. Front Physiol 11: 1039.

    [Crossref] [Google Scholar] [PubMed]

68. Vaira LA, Salzano G, Fois AG, Piombino P, Riu GD (2020) Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int Forum Allergy Rhinol 10: 1103-1104.

    [Crossref] [Google Scholar] [PubMed]

69. Doyle ME, Appleton A, Liu QR, Yao Q, Mazucanti CH, et al. (2021) Human type II taste cells express angiotensin-converting enzyme 2 and are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Am J Pathol 191: 1511-1519.

    [Crossref] [Google Scholar] [PubMed]

70. Srinivasan M (2021) Taste dysfunction and long COVID-19. Front Cell Infect Microbiol 11: 716563

    [Crossref] [Google Scholar] [PubMed]

71. Cazzolla AP, Lovero R, Muzio LL, Testa NF, Schirinzi A, et al. (2020) Taste and smell disorders in COVID-19 patients: Role of interleukin-6. ACS Chem Neurosci 11: 2774-2781.

    [Crossref] [Google Scholar] [PubMed]

72. Lozada-Nur F, Chainani-Wu N, Fortuna G, Sroussi H (2020) Dysgeusia in COVID-19: Possible mechanisms and implications. Oral Surg Oral Med Oral Pathol Oral Radiol 130: 344-346.

    [Crossref] [Google Scholar] [PubMed]

73. Mahmoud MM, Abuohashish HM, Khairy DA, Bugshan AS, Khan AM, et al. (2021) Pathogenesis of dysgeusia in COVID-19 patients: A scoping review. Eur Rev Med Pharmacol Sci 25: 1114-1134.

    [Crossref] [Google Scholar] [PubMed]

74. Mastrangelo A, Bonato M, Cinque P (2021) Smell and taste disorders in COVID-19: From pathogenesis to clinical features and outcomes. Neurosci Lett 748: 135694.

    [Crossref] [Google Scholar] [PubMed]

75. Otsubo Y, Miyagi M, Sekiya H, Kano O, Ebihara S (2022) Improving taste sensitivity in healthy adults using taste recall training: a randomized controlled trial. Sci Rep 12: 13849.

    [Crossref] [Google Scholar] [PubMed]

76. Singh CV, Jain S, Parveen S (2021) The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. Am J Otolaryngol 42:102892.

    [Crossref] [Google Scholar] [PubMed]

77. Li Z, Liu Y, Wei R, Yong VW, Xue M (2022) The important role of zinc in neurological diseases. Biomolecules 13: 28.

    [Crossref] [Google Scholar] [PubMed]

78. Troyer EA, Kohn JN, Hong S (2020) Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun 87: 34-39.

    [Crossref] [Google Scholar] [PubMed]

79. Liu D, Baumeister RF, Zhou Y (2021) Mental health outcomes of coronavirus infection survivors: A rapid meta-analysis. J Psychiatr Res 137: 542-553.

    [Crossref] [Google Scholar] [PubMed]

80. Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, et al. (2021) Persistent neuropsychiatric symptoms after COVID-19: A systematic review and meta-analysis. Brain Commun 4: fcab297.

    [Crossref] [Google Scholar] [PubMed]

81. Mazza MG, Palladini M, Poletti S, Benedetti F (2022) Post-COVID-19 depressive symptoms: Epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs 36: 681-702.

    [Crossref] [Google Scholar] [PubMed]

82. Cereda G, Ciappolino V, Boscutti A, Cantù F, Enrico P, et al. (2022) Zinc as a neuroprotective nutrient for COVID-19-related neuropsychiatric manifestations: A literature review. Adv Nutr 13: 66-79.

    [Crossref] [Google Scholar] [PubMed]